Delisting riskPopularity #3,172
OTLK · NASDAQ · Biotechnology

Outlook Therapeutics (OTLK)

Develops and commercializes ophthalmic bevacizumab for wet age-related macular degeneration.

$0.6732
vs last close−0.02 (−3.30%)